Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

MEDRAD to establish partnership with University of South Florida and Moffitt Cancer Center to Study Workflow and Process Improvements in PET Imaging

MEDRAD, Inc. has signed a research agreement with the University of South Florida (USF) to study the impact of automated Fluoro-deoxy-glucose (FDG) administration on the workflow for Positron Emission Tomography (PET) imaging procedures.  Clinicians at Moffitt Cancer Center in Tampa, Florida will utilize MEDRAD’s Intego PET Infusion System to measure and infuse patient-specific FDG doses while industrial engineers from USF gather and analyze workflow data.

The study is designed to compare manual infusion to automated infusion, and to quantify time, cost, and labor savings that is expected to result from the process improvements enabled by automated FDG infusion. The Intego System improves workflow by eliminating manual steps in the preparation and handling of patient doses through design that incorporates a multi-dose FDG vial and dose-on-demand technology.  Intego also provides safety and accuracy benefits by reducing radiation exposure from dose preparation and infusion by at least 20% and infusing FDG within +/-2% of the measured dose.

The Intego System automatically extracts a patient dose from a multi-dose vial and infuses it directly into the patient, virtually eliminating manual dose preparation and handling and the corresponding radiation exposure to the technologist inherent in manual preparation. With the Intego System’s dose-on-demand capability, the prescribed dose can be delivered when the patient and clinician are ready. This enables the clinician to easily and efficiently respond to schedule changes, patient delays, and add-on patients. Innovative features, including real-time dose availability information, an integrated ionization chamber, and an optional weight-based dose calculation, allow the healthcare provider to customize each patient’s dose. Safety features include a tungsten multi-dose vial shield, a fully lead-lined mobile cart, and an automated saline flush to remove residual FDG from the line after each infusion.

Source: MEDRAD